BACKGROUND: A major complication associated with cardiac surgery is excessive and prolonged bleeding in the perioperative period. Improving coagulation by inhibiting fibrinolysis, primarily through inhibition of plasmin activity (PLact) with antifibrinolytics such as tranexamic acid (TXA), has been a pharmacological mainstay in cardiac surgical patients. Despite its almost ubiquitous use, the temporal and regional modulation of PLact profiles by TXA remains unexplored. Accordingly, we developed a fluorogenic-microdialysis system to measure in vivo dynamic changes in PLact after TXA administration in a large animal model. METHODS: Pigs (25-35 kg) were randomly assigned to receive TXA (30 mg/kg, diluted into 50 mL normal saline; n ϭ 9) or veh...
BACKGROUND: Although recent studies have assessed tranexamic acid (TXA) pharmacokinetics in differen...
Understanding the coagulation process is critical to developing treatments for trauma and coagulopat...
AbstractChildren undergoing cardiac operations in which cardiopulmonary bypass is used are at risk o...
Background—A major complication associated with cardiac surgery is excessive and prolonged bleeding ...
Essentials Tranexamic acid (TXA) is an antifibrinolytic drug used to reduce bleeding. Assaying plasm...
Abstract Tranexamic acid (TXA) is a widely used antifibrinolytic agent that has been used since the ...
Tranexamic acid (TXA) is an antifibrinolytic agent that blocks plasmin formation. Because plasmin is...
Background: Tranexamic acid (TXA) is increasingly used during major surgery with the goal to reduce ...
Objective: To understand more about the individual variation in the time course of fibrinolysis foll...
AbstractObjective: Desmopressin releases tissue-type plasminogen activator, which augments cardiopul...
: Intravenous tranexamic acid (TXA) reduces death because of bleeding in patients with trauma and po...
Local and systemic application of tranexamic acid in heart valve surgery: a prospective, randomized,...
Tranexamic acid (TXA) is a popular antifibrinolytic drug widely used in hemorrhagic trauma patients ...
Trauma and hemorrhagic shock can lead to acute traumatic coagulopathy (ATC) that is not fully revers...
Cardiopulmonary bypass is frequently associated with excessive blood loss. Platelet dysfunction is t...
BACKGROUND: Although recent studies have assessed tranexamic acid (TXA) pharmacokinetics in differen...
Understanding the coagulation process is critical to developing treatments for trauma and coagulopat...
AbstractChildren undergoing cardiac operations in which cardiopulmonary bypass is used are at risk o...
Background—A major complication associated with cardiac surgery is excessive and prolonged bleeding ...
Essentials Tranexamic acid (TXA) is an antifibrinolytic drug used to reduce bleeding. Assaying plasm...
Abstract Tranexamic acid (TXA) is a widely used antifibrinolytic agent that has been used since the ...
Tranexamic acid (TXA) is an antifibrinolytic agent that blocks plasmin formation. Because plasmin is...
Background: Tranexamic acid (TXA) is increasingly used during major surgery with the goal to reduce ...
Objective: To understand more about the individual variation in the time course of fibrinolysis foll...
AbstractObjective: Desmopressin releases tissue-type plasminogen activator, which augments cardiopul...
: Intravenous tranexamic acid (TXA) reduces death because of bleeding in patients with trauma and po...
Local and systemic application of tranexamic acid in heart valve surgery: a prospective, randomized,...
Tranexamic acid (TXA) is a popular antifibrinolytic drug widely used in hemorrhagic trauma patients ...
Trauma and hemorrhagic shock can lead to acute traumatic coagulopathy (ATC) that is not fully revers...
Cardiopulmonary bypass is frequently associated with excessive blood loss. Platelet dysfunction is t...
BACKGROUND: Although recent studies have assessed tranexamic acid (TXA) pharmacokinetics in differen...
Understanding the coagulation process is critical to developing treatments for trauma and coagulopat...
AbstractChildren undergoing cardiac operations in which cardiopulmonary bypass is used are at risk o...